SERB Pharmaceuticals to Acquire Y-mAbs Therapeutics in $412 Million
Wednesday, August 06, 2025
SERB Pharmaceuticals has announced the acquisition of Y-mAbs Therapeutics.
The agreement values Y-mAbs at approximately $412 million in an all-cash transaction.
Under the terms of the deal, SERB will launch a tender offer to purchase all outstanding shares of Y-mAbs common stock at $8.60 per share. This offer represents a premium of around 105 per cent compared to Y-mAbs’ closing share price on 4 August 2025, the last trading day before the announcement.
The Y-mAbs Board of Directors unanimously approved the transaction after reviewing various strategic alternatives to maximise shareholder value. This process involved discussions with multiple potential buyers and consideration of additional capital options to support the company’s development pipeline.
Y-mAbs is known for developing DANYELZA® (naxitamab-gqgk), the first FDA-approved treatment for relapsed or refractory high-risk neuroblastoma. This rare and aggressive paediatric cancer typically affects children and young adults. The therapy, administered either in hospital or in outpatient settings, has expanded treatment options for neuroblastoma patients and their families.
Alongside DANYELZA, Y-mAbs’ pipeline includes early-stage investigational therapies, notably through its SADA pretargeted radioimmunotherapy platform. These include potential treatments targeting GD2 in solid tumours and CD38 in circulating tumours.
For SERB, the acquisition is expected to enhance its rare oncology portfolio, which already includes Voraxaze®, Vistogard®, and Xermelo®. The company aims to utilise its global footprint and expertise to support the wider availability of DANYELZA and continue developing Y-mAbs’ pipeline.
The acquisition is aligned with SERB’s broader strategy of expanding its presence in rare disease and oncology markets, particularly in the United States, where it has been building its operations over the past five years.
Source: serb.com
